Aptose Financial Statements From 2010 to 2024

APTO Stock  USD 0.18  0.01  5.26%   
Aptose Biosciences financial statements provide useful quarterly and yearly information to potential Aptose Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Aptose Biosciences financial statements helps investors assess Aptose Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Aptose Biosciences' valuation are summarized below:
Market Capitalization
10.8 M
Earnings Share
(2.92)
We have found one hundred twenty available fundamental signals for Aptose Biosciences, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Aptose Biosciences' prevailing fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 30th of November 2024, Market Cap is likely to grow to about 4.6 M, though Enterprise Value is likely to grow to (35.1 M).
Check Aptose Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aptose Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 83.6 K, Interest Expense of 929.8 K or Selling General Administrative of 16.4 M, as well as many indicators such as Price To Sales Ratio of 12.36, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Aptose financial statements analysis is a perfect complement when working with Aptose Biosciences Valuation or Volatility modules.
  
Check out the analysis of Aptose Biosciences Correlation against competitors.
To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.

Aptose Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets12.3 M13 M31.9 M
Slightly volatile
Other Current Liabilities9.3 M8.8 M3.2 M
Slightly volatile
Total Current Liabilities16 M15.3 M5.3 M
Slightly volatile
Property Plant And Equipment Net574.5 K1.1 M564.2 K
Slightly volatile
Accounts Payable6.3 MM1.9 M
Slightly volatile
Cash15.8 M9.3 M24.1 M
Slightly volatile
Non Current Assets Total1.7 M1.1 M687.3 K
Slightly volatile
Cash And Short Term Investments8.8 M9.3 M30 M
Slightly volatile
Common Stock Shares Outstanding7.1 M6.8 M2.8 M
Slightly volatile
Liabilities And Stockholders Equity12.3 M13 M31.9 M
Slightly volatile
Other Current Assets2.8 M2.6 M1.1 M
Slightly volatile
Other Stockholder Equity75.8 M72.1 M38.5 M
Slightly volatile
Total Liabilities16.7 M15.9 M5.6 M
Slightly volatile
Property Plant And Equipment Gross4.1 M3.9 M882.8 K
Slightly volatile
Total Current Assets11.3 M11.9 M31.2 M
Slightly volatile
Common Stock231.5 M444.8 M263.5 M
Slightly volatile
Property Plant Equipment364.1 K189.9 K369.7 K
Slightly volatile
Short and Long Term Debt Total964.2 KM1.7 M
Slightly volatile
Capital Surpluse51.4 M79.2 M41.1 M
Slightly volatile
Capital Stock435.6 M444.8 M326.7 M
Slightly volatile
Long Term Debt Total808.8 K909.9 K990.8 K
Slightly volatile
Capital Lease Obligations879.7 KM1.3 M
Slightly volatile
Non Current Liabilities Other808.8 K909.9 K990.8 K
Slightly volatile

Aptose Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization83.6 K88 K222.6 K
Slightly volatile
Selling General Administrative16.4 M15.6 M9.7 M
Slightly volatile
Other Operating Expenses55 M52.4 M26.1 M
Slightly volatile
Research Development38.6 M36.8 M16.3 M
Slightly volatile
Total Operating Expenses55 M52.4 M26.1 M
Slightly volatile
Selling And Marketing Expenses162.7 K171.2 K156.1 K
Pretty Stable
Interest Income1.5 M1.4 M812.8 K
Pretty Stable
Net Interest Income1.5 M1.4 M380.5 K
Slightly volatile
Reconciled Depreciation472.1 K456 K270.9 K
Slightly volatile
Non Operating Income Net Other488.6 K895.9 K367.8 K
Slightly volatile

Aptose Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow38.8 M37 M24.6 M
Slightly volatile
Other Cashflows From Financing Activities27.6 K29 K9.6 M
Pretty Stable
Depreciation654.2 K466 K291.4 K
Slightly volatile
Total Cash From Financing Activities6.6 M6.9 M18.7 M
Pretty Stable
End Period Cash Flow15.8 M9.3 M24.1 M
Slightly volatile
Stock Based Compensation3.8 M3.7 M3.9 M
Slightly volatile
Issuance Of Capital Stock5.8 M6.1 M26.3 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio12.3613.0112.3496
Slightly volatile
Invested Capital21.4 M24 M26.2 M
Slightly volatile
Average Payables322.3 K339.3 K393.2 K
Slightly volatile
Capex To Depreciation0.05910.06221.4083
Slightly volatile
EV To Sales13.0912.4713.1958
Slightly volatile
Sales General And Administrative To Revenue47.1127.5626.7184
Pretty Stable
Research And Ddevelopement To Revenue20.9922.120.1771
Pretty Stable
Capex To Revenue0.01670.01760.1478
Slightly volatile
Cash Per Share1.31.369796.4619
Slightly volatile
Income Quality0.620.87080.777
Pretty Stable
Tangible Asset Value21 M23.6 M25.7 M
Slightly volatile
Current Ratio0.740.7797.9291
Very volatile
Receivables Turnover0.40.450.49
Slightly volatile
Graham Number8.138.5586326
Slightly volatile
Capex Per Share0.00410.00431.4355
Slightly volatile
Revenue Per Share5.052.743.2994
Slightly volatile
Interest Debt Per Share0.110.098817.7396
Slightly volatile
Debt To Assets0.00470.00490.1221
Slightly volatile
Ebt Per Ebit0.620.97810.9657
Slightly volatile
Long Term Debt To Capitalization0.02060.02170.0468
Slightly volatile
Quick Ratio0.740.7797.9291
Very volatile
Net Income Per E B T0.790.880.9613
Slightly volatile
Cash Ratio0.580.60595.4235
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.171.00071.0206
Pretty Stable
Fixed Asset Turnover0.840.80.8334
Slightly volatile
Debt Ratio0.00470.00490.1221
Slightly volatile
Price Sales Ratio12.3613.0112.3496
Slightly volatile
Asset Turnover0.05380.05120.0531
Slightly volatile
Gross Profit Margin1.041.195.4387
Slightly volatile
Operating Cycle584657715
Slightly volatile

Aptose Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.6 M3.2 M5.6 M
Slightly volatile

Aptose Fundamental Market Drivers

Cash And Short Term Investments9.3 M

Aptose Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Aptose Biosciences Financial Statements

Aptose Biosciences investors utilize fundamental indicators, such as revenue or net income, to predict how Aptose Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.3 M-2.2 M
Cost Of Revenue474.5 K498.3 K
Sales General And Administrative To Revenue 27.56  47.11 
Research And Ddevelopement To Revenue 22.10  20.99 
Capex To Revenue 0.02  0.02 
Revenue Per Share 2.74  5.05 
Ebit Per Revenue(38.56)(40.48)

Pair Trading with Aptose Biosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptose Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptose Biosciences will appreciate offsetting losses from the drop in the long position's value.

Moving against Aptose Stock

  0.7ESPR Esperion Therapeutics Buyout TrendPairCorr
  0.63VTRS ViatrisPairCorr
  0.58BMY Bristol Myers Squibb Sell-off TrendPairCorr
  0.44BFRIW Biofrontera WarrantsPairCorr
  0.39WAT WatersPairCorr
The ability to find closely correlated positions to Aptose Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptose Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptose Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptose Biosciences to buy it.
The correlation of Aptose Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptose Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptose Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptose Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Aptose Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptose Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptose Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptose Biosciences Stock:
Check out the analysis of Aptose Biosciences Correlation against competitors.
To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptose Biosciences. If investors know Aptose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptose Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.92)
Return On Assets
(1.36)
Return On Equity
(6.94)
The market value of Aptose Biosciences is measured differently than its book value, which is the value of Aptose that is recorded on the company's balance sheet. Investors also form their own opinion of Aptose Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aptose Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptose Biosciences' market value can be influenced by many factors that don't directly affect Aptose Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptose Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptose Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.